These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1066 related articles for article (PubMed ID: 31870811)

  • 21. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
    de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
    Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
    Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
    Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel nine-microRNA-based model to improve prognosis prediction of renal cell carcinoma.
    Xu C; Zeng H; Fan J; Huang W; Yu X; Li S; Wang F; Long X
    BMC Cancer; 2022 Mar; 22(1):264. PubMed ID: 35279104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial.
    Hakimi AA; Voss MH; Kuo F; Sanchez A; Liu M; Nixon BG; Vuong L; Ostrovnaya I; Chen YB; Reuter V; Riaz N; Cheng Y; Patel P; Marker M; Reising A; Li MO; Chan TA; Motzer RJ
    Cancer Discov; 2019 Apr; 9(4):510-525. PubMed ID: 30622105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
    de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
    Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Body Mass Index on Perioperative Complications and Oncologic Outcomes in Patients Undergoing Thermal Ablation for Renal Cell Carcinoma.
    Zhou W; Herwald SE; Uppot RN; Arellano RS
    J Vasc Interv Radiol; 2021 Jan; 32(1):33-38. PubMed ID: 33308948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overweight is associated with improved cancer-specific survival in patients with organ-confined renal cell carcinoma.
    Schrader AJ; Rustemeier J; Rustemeier JC; Timmesfeld N; Varga Z; Hegele A; Olbert PJ; Hofmann R
    J Cancer Res Clin Oncol; 2009 Dec; 135(12):1693-9. PubMed ID: 19543914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study.
    Wei JH; Feng ZH; Cao Y; Zhao HW; Chen ZH; Liao B; Wang Q; Han H; Zhang J; Xu YZ; Li B; Wu JT; Qu GM; Wang GP; Liu C; Xue W; Liu Q; Lu J; Li CX; Li PX; Zhang ZL; Yao HH; Pan YH; Chen WF; Xie D; Shi L; Gao ZL; Huang YR; Zhou FJ; Wang SG; Liu ZP; Chen W; Luo JH
    Lancet Oncol; 2019 Apr; 20(4):591-600. PubMed ID: 30880070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications.
    Aurilio G; Piva F; Santoni M; Cimadamore A; Sorgentoni G; Lopez-Beltran A; Cheng L; Battelli N; Nolè F; Montironi R
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31766196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
    Tsimafeyeu I; Zart JS; Chung B
    BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma.
    Donin NM; Pantuck A; Klöpfer P; Bevan P; Fall B; Said J; Belldegrun AS; Chamie K
    Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1326-32. PubMed ID: 27418270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of obesity and adiponectin signaling in patients with renal cell carcinoma: A potential mechanism for the "obesity paradox".
    Ito R; Narita S; Huang M; Nara T; Numakura K; Takayama K; Tsuruta H; Maeno A; Saito M; Inoue T; Tsuchiya N; Satoh S; Habuchi T
    PLoS One; 2017; 12(2):e0171615. PubMed ID: 28178338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival.
    Chong TW; Goh FY; Sim MY; Huang HH; Thike AA; Lim WK; Teh BT; Tan PH
    J Clin Pathol; 2015 Mar; 68(3):200-5. PubMed ID: 25477528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy.
    Spiess PE; Kurian T; Lin HY; Rawal B; Kim T; Sexton WJ; Pow-Sang JM
    BJU Int; 2012 Dec; 110(11 Pt B):E470-4. PubMed ID: 22519938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of expression levels of miR-21 and miR-126 is associated with cancer-specific survival in clear-cell renal cell carcinoma.
    Vergho D; Kneitz S; Rosenwald A; Scherer C; Spahn M; Burger M; Riedmiller H; Kneitz B
    BMC Cancer; 2014 Jan; 14():25. PubMed ID: 24428907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Overweight is an advantageous prognostic marker in patients with clear cell kidney cancer].
    Waalkes S; Eggers H; Rustemeier J; Wegener G; Jentzmik F; Schrader M; Hofmann R; Kuczyk MA; Schrader AJ;
    Urologe A; 2011 Sep; 50(9):1118-24. PubMed ID: 21720831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression.
    Marcon J; DiNatale RG; Sanchez A; Kotecha RR; Gupta S; Kuo F; Makarov V; Sandhu A; Mano R; Silagy AW; Blum KA; Nassau DE; Benfante NE; Ortiz MV; Carlo MI; Chan TA; Motzer RJ; Voss MH; Coleman J; Russo P; Reuter V; Hakimi AA; Reznik E
    Clin Cancer Res; 2020 Jul; 26(14):3629-3640. PubMed ID: 32220885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
    Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS
    Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.
    Mendoza-Pérez J; Gu J; Herrera LA; Tannir NM; Zhang S; Matin S; Karam JA; Wood CG; Wu X
    Cancer; 2017 Sep; 123(18):3617-3627. PubMed ID: 28543182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of computed tomography-based body composition with survival in metastatic renal cancer patient received immunotherapy: a multicenter, retrospective study.
    Wang J; Dong P; Qu Y; Xu W; Zhou Z; Ning K; Peng Y; Xiong L; Li Z; Zou X; Liu Z; Li M; He Z; Luo J; Tian X; Zhang H; Guo S; Han H; Zhou F; Yin S; Ye D; Yu C; Zhang Z
    Eur Radiol; 2023 May; 33(5):3232-3242. PubMed ID: 36538073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.